<DOC>
	<DOCNO>NCT02128971</DOCNO>
	<brief_summary>The purpose study compare gastrointestinal ( GI ) tolerability 5 different iron supplement ( Ferrochel® , Sumalate® , ferrous fumarate , ferrous sulfate ferric glycinate ) dose ( 90mg ) placebo .</brief_summary>
	<brief_title>A Study Compare Gastrointestinal Tolerability Ferrochel® , Sumalate® , Ferrous Fumarate , Ferrous Sulfate , Ferric Glycinate , Placebo</brief_title>
	<detailed_description>Anemia , common disorder blood , characterize decrease number red blood cell ( RBCs ) less normal quantity hemoglobin blood.Hemoglobin oxygen-carrying protein inside RBCs transport oxygen respiratory organs rest body . Several vitamin , mineral nutrient require development production RBCs , vitamin B12 , folic acid iron . Iron essential component hemoglobin . Iron deficiency account half anemia case worldwide , iron deficiency anemia common nutritional disorder world.Iron deficiency result inadequate intake diet , poor absorption , extra need growth pregnancy , blood loss . Thus , child woman high risk . Full blood count hemoglobin measurement use diagnose anemia , measurement serum ferritin level ( cutoff 12-15 mg/l ) consider best single non-invasive test diagnosis iron-deficiency . Treatment anemia depend cause severity . Oral iron supplement simple cost-effective option treat anemia replenish body storage . The objective clinical trial compare gastrointestinal ( GI ) tolerability 5 different iron supplement ( Ferrochel® , Sumalate® , ferrous fumarate , ferrous sulfate ferric glycinate ) dose ( 90mg ) placebo . The primary objective compare gastrointestinal tolerability quote product : - Self-assessment questionnaire - Gastrointestinal Symptoms Questionnaire5 - Self report diary The Secondary objective study assess change baseline parameter : - Hemoglobin level - Hematocrit level - Ferritin level This prospective clinical trial single-center , six-arms , randomize , double-blinded , parallel study . Subject screen accord inclusion exclusion criterion , blood sample collect ensure hemoglobin ferritin level . Subject also ask complete Gastrointestinal Symptoms Questionnaire . The study product administer 30 day , orally daily morning breakfast . The study plan follow : Visit 1 : Screening / Baseline ( day -7 ) 1 . Protocol information give investigator potential subject . Each participant sign consent form explain entail participate study well provide subject information report adverse event ( AEs ) may arise . 2 . Collection demographic information medical history . 3 . A 10-mL blood sample collect venipuncture lab analysis hemoglobin ferritin . 4 . Subjects complete Gastrointestinal Symptoms Questionnaire baseline record . 5 . Subjects meet inclusion exclusion criterion schedule visit 2 Visit 2 : Day 0 1 . PI designee assign unique subject ID number eligible subject ascend order ; subject ID corresponds assign investigational product code subject list label investigational product ( IP ) give subject . 2 . Subjects complete Gastrointestinal Symptoms Questionnaire . 3 . A 10-ml blood sample collect venipuncture lab analysis hemoglobin , ferritin hematocrit . 4 . Subject diary dispense . 5 . The PI designee dispense investigational product capsule subject , accord subject list provide . Each subject receive sufficient investigational product capsule last 30 day . 6 . Subjects begin consume investigational product capsule day , time breakfast , 30 day start Day 1 . Visit 3 : Day 15 Window period ± 2 day allow visit 1 . A 10-ml blood sample collect venipuncture lab analysis hemoglobin , ferritin hematocrit . 2 . Subjects bring unused IP study site . Compliance monitor count remain investigational product capsule . The remain IP capsule return subject . 3 . Subjects complete Gastrointestinal Symptoms Questionnaire . 4 . Subject 's diary collect new diary dispense . Visit 4 : Day 30 Window period ± 2 day allow visit 1 . A 10-mlblood sample collect venipuncture lab analysis hemoglobin , ferritin hematocrit . 2 . The PI designee collect remain investigational product . Compliance monitor count remain investigational product capsule . 3 . Subjects complete Gastrointestinal Symptoms Questionnaire . 4 . Subject 's diary collect . 5 . New Subject diary dispense . Visit 5 : Day 37 Window period ± 2 day allow visit 1 . Subjects complete Gastrointestinal Symptoms Questionnaire . 2 . Subject diary collect . Adverse Event Serious Adverse Event record since subject begin consume investigational product throughout study . SAE record SAE form report Sponsor CRA within 24 hour . All SAE report Ethic Committee Regulatory Authority .</detailed_description>
	<mesh_term>Ferrous fumarate</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>1 . Women , 1850 year age , inclusive 2 . Hemoglobin 8 g/dl 11 g/dl 3 . Ferritin level &lt; 20 mcg/l ( 20 ng/mL ) 4 . Subject , subject 's acceptable representative , voluntarily sign date informed consent form , approve local Ethics Committee/Institutional Review Board prior participation study 1 . Pregnant lactate 2 . Amenorrhea 3 . Severe anemia ( hemoglobin 7 g/dl ) blood abnormality ( e.g. , leukopenia , thrombocytopenia , polycythemia vera ) 4 . Serious illness may confound study result interfere compliance 5 . Subjects follow specific diet , eg . high protein diet , within 30 day prior study start 6 . Subjects take iron supplement within 30 day prior study start 7 . Subjects allergic ingredient product 8 . Participation clinical trial within three month prior screen 9 . Known intolerance oral iron supplement 10 . Habitual smoker ( 3 cigarette per week ) 11 . Other medical condition , investigator 's opinion , may confound study result prelude subject 's ability safely complete trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Iron supplement study</keyword>
</DOC>